These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30376198)

  • 1. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells.
    Cadoni E; Vanhara P; Valletta E; Pinna E; Vascellari S; Caddeo G; Isaia F; Pani A; Havel J; Pivetta T
    Rapid Commun Mass Spectrom; 2019 Jan; 33(1):97-106. PubMed ID: 30376198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed copper-platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESI-MS study.
    Pivetta T; Lallai V; Valletta E; Trudu F; Isaia F; Perra D; Pinna E; Pani A
    J Inorg Biochem; 2015 Oct; 151():107-14. PubMed ID: 26021964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
    Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
    J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversed phase and cation exchange liquid chromatography with spectrophotometric and elemental/molecular mass spectrometric detection for S-adenosyl methionine/S-adenosyl homocysteine ratios as methylation index in cell cultures of ovarian cancer.
    Iglesias González T; Cinti M; Montes-Bayón M; Fernández de la Campa MR; Blanco-González E
    J Chromatogr A; 2015 May; 1393():89-95. PubMed ID: 25836049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
    Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
    Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method.
    Gong F; Peng X; Zeng Z; Yu M; Zhao Y; Tong A
    Mol Cell Biochem; 2011 Feb; 348(1-2):141-7. PubMed ID: 21080034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry.
    Houjou T; Yamatani K; Imagawa M; Shimizu T; Taguchi R
    Rapid Commun Mass Spectrom; 2005; 19(5):654-66. PubMed ID: 15700236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
    Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
    Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study.
    Lee RFS; Riedel T; Escrig S; Maclachlan C; Knott GW; Davey CA; Johnsson K; Meibom A; Dyson PJ
    Metallomics; 2017 Oct; 9(10):1413-1420. PubMed ID: 28913538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
    Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines.
    Ghini V; Sorbi F; Fambrini M; Magherini F
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthesis, chemical and biological properties of dichlorido(azpy)gold(III) chloride (azpy=2-(phenylazo)pyridine) and the gold-induced conversion of the azpy ligand to the chloride of the novel tricyclic pyrido[2,1-c][1,2,4]benzotriazin-11-ium cation.
    Garza-Ortiz A; den Dulk H; Brouwer J; Kooijman H; Spek AL; Reedijk J
    J Inorg Biochem; 2007 Nov; 101(11-12):1922-30. PubMed ID: 17637477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.
    Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H
    Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
    Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
    Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.